HomeBusinessHealthcare Industry Stock NewsGSK (GSK) To Acquire Bellus Health (BLU) For $2B

GSK (GSK) To Acquire Bellus Health (BLU) For $2B

GSK (GSK) reaches agreement to acquire Bellus Health (BLU). George Tsilis joins Alex Coffey and Jenny Horne to discuss this as the deal is worth approximately $2B or $14.75 per share. He talks about how the deal is expected to close in 3Q23 or earlier. BLU is a late-stage biopharma company whose experimental cough medicine "Camlipixant" is expected to launch in 2026. Tune in to find out more about the stock market today.

ON AIR
4:30 am
Next Gen Investing
replay
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
ON AIR
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
education
3:30 pm
Your First Trade
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
education
7:00 pm
Your First Trade
REPLAY
7:30 pm
Trading 360
REPLAY
8:30 pm
Fast Market
REPLAY
9:30 pm
Next Gen Investing
REPLAY
education
10:30 pm
Your First Trade
REPLAY
11:00 pm
Trading 360
REPLAY

Get Market Minute

Daily insights for every investor

FOLLOW US